Designation of Denosumab (XGEVA) as an orphan drug - Amgen Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, aiming to ensure the safety, quality, and efficacy of these products. One of the critical functions of this legislation is to address the gap in the availability of treatments for rare diseases, often referred to as "orphan drugs." This particular designation under the Act, performed by Dr. Anthony Gill as a delegate of the Secretary, recognises denosumab (XGEVA) as an orphan drug for treating hypercalcaemia of malignancy that is resistant to intravenous bisphosphonates. The policy objective here is to encourage the development and availability of treatments for rare and life-threatening conditions, ensuring that patients with such conditions have access to potentially life-saving therapies. The enactment of this specific designation underscores the legislative commitment to addressing the needs of patients with rare diseases, facilitating the provision of targeted treatments that might otherwise not be economically viable for pharmaceutical companies to develop.

Scope and Application

The Therapeutic Goods Act 1989 designates specific therapeutic goods for particular medical conditions, including the designation of denosumab (XGEVA) as an orphan drug for the treatment of hypercalcaemia of malignancy that is refractory to intravenous bisphosphonates. This designation applies to the solution for injection dose form of denosumab (XGEVA), as sponsored by Amgen Australia Pty Ltd. The Act operates at the Commonwealth level, under the purview of the Therapeutic Goods Administration, ensuring that the therapeutic goods available in Australia meet safety, quality, and efficacy standards. This legislative action extends to regulating the use and distribution of designated orphan drugs within Australia, aiming to facilitate access to treatments for rare diseases. The Act does not specify any exclusions or exemptions for this designation but operates within the broader regulatory framework of the Therapeutic Goods Act 1989 and its associated regulations, which may include provisions for further clarification or restriction of application through subordinate instruments.

Key Provisions

The Therapeutic Goods Act 1989 (Cth), through the Therapeutic Goods Regulations 1990, designates denosumab (XGEVA) as an orphan drug for the treatment of hypercalcaemia of malignancy that is refractory to intravenous bisphosphonates. This designation (Regulation 16J) was made by Dr Anthony Gill, acting as the Delegate of the Secretary, on 27 June 2014. This particular orphan drug status applies to the solution for injection dose form of denosumab (XGEVA), and the sponsor of the drug is Amgen Australia Pty Ltd. The main purpose of this designation is to encourage the development of drugs that treat rare conditions by providing certain benefits and incentives to the sponsor. Under this Act and the Regulations, the sponsor of the orphan drug, in this case Amgen Australia Pty Ltd, is afforded certain advantages. These may include a streamlined approval process, potential financial incentives, and priority review of applications to ensure that treatments for rare conditions are brought to market more efficiently. The Act and Regulations outline the criteria for orphan drug designation, which includes the rarity of the condition, the unmet medical need, and the potential benefits of the drug in treating the condition. The Therapeutic Goods Act 1989 and the Regulations impose specific obligations on the sponsor of the orphan drug. These include maintaining records of the drug's development, clinical trials, and any marketing authorisations. The sponsor must also ensure that the drug complies with all quality, safety, and efficacy standards set out in the Act and Regulations. Furthermore, the sponsor is required to report any adverse events or changes in the drug's safety profile to the Therapeutic Goods Administration. These obligations are crucial in ensuring that the orphan drug is safe and effective for its intended use. Breaching the obligations set out in the Therapeutic Goods Act 1989 and the Regulations can result in various penalties and consequences. For instance, failure to maintain proper records, report adverse events, or comply with quality standards can lead to fines, suspension of marketing authorisations, or even prosecution. The maximum penalties for breaches of the Act can include substantial fines for individuals and corporations, depending on the severity and frequency of the breach. In some cases, criminal charges may be brought against individuals responsible for the breach, leading to imprisonment. These penalties serve as a deterrent against non-compliance and ensure that the therapeutic goods available in Australia meet the necessary standards of quality, safety, and efficacy.